• Harmony Biosciences Holdings, Inc. recently reported second-quarter 2026 results showing net income of US$75.43 million and diluted earnings per share of US$1.28, both higher than a year earlier, and confirmed completion of a share repurchase program begun in October 2023.
• Earlier this month, the company also appeared at the Piper Sandler Virtual CNS Symposium, highlighting its focus on therapies for rare and other neurological conditions as it builds on this improved profitability.
• With significantly higher quarterly earnings now on the table, we’ll examine how this profit growth influences Harmony Biosciences’ existing investment narrative.

Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

Harmony Biosciences Holdings Investment Narrative Recap

To own Harmony Biosciences, you need to believe that WAKIX and a focused neurology portfolio can support durable profitability while the company gradually broadens beyond a single flagship drug. The latest jump in quarterly earnings reinforces the profit story but does not fundamentally change the near term catalyst around late stage pipeline progress or reduce the key risk of heavy dependence on WAKIX and eventual generic or competing therapies.

The most relevant recent development here is Harmony’s completion of its roughly US$50.0 million share repurchase program covering about 3.1% of shares outstanding. Set alongside stronger Q2 2026 earnings, this capital return frames a company that is currently generating enough profit to support buybacks while still facing the same fundamental catalyst in regulatory and clinical milestones, and the same core risk in concentration around a single commercial product.

Yet against these stronger near term earnings, the risk that WAKIX concentration and future competition could pressure margins remains something investors should be aware of...

Harmony Biosciences Holdings' narrative projects $1.2 billion revenue and $333.5 million earnings by 2028. This requires 17.0% yearly revenue growth and about a $152.6 million earnings increase from $180.9 million today.

Uncover how Harmony Biosciences Holdings' forecasts yield a $47.30 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were assuming Harmony’s revenue would shrink about 5% a year and earnings fall to roughly US$98 million, so this earnings beat may prompt you to reassess how much weight you give that more cautious view versus the concentration and pricing risks discussed earlier.

Explore 4 other fair value estimates on Harmony Biosciences Holdings - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Harmony Biosciences Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 52 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.